Published in Leukemia on September 01, 1998
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood (2009) 3.40
PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci U S A (2002) 3.19
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood (2005) 2.22
Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Leuk Lymphoma (2008) 1.93
Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn (2003) 1.82
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell (2007) 1.74
Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res (2009) 1.72
Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Blood (2008) 1.67
FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood (2009) 1.59
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood (2006) 1.52
FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat (2009) 1.47
FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm. Cell Stem Cell (2012) 1.39
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol (2014) 1.28
Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell (2011) 1.24
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant (2014) 1.20
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood (2005) 1.18
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood (2008) 1.09
FLT3 inhibitors: a story of the old and the new. Curr Opin Hematol (2011) 1.09
FLT3/ITD AML and the law of unintended consequences. Blood (2011) 1.07
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. Oncologist (2011) 1.05
Further activation of FLT3 mutants by FLT3 ligand. Oncogene (2011) 1.04
Bench to bedside targeting of FLT3 in acute leukemia. Curr Drug Targets (2010) 1.03
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood (2008) 1.01
Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. Adv Enzyme Regul (2007) 1.01
High-resolution melting analysis for detection of internal tandem duplications. J Mol Diagn (2004) 1.01
Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases. Nat Rev Cancer (2012) 0.99
Treatment of FLT3-ITD acute myeloid leukemia. Am J Blood Res (2011) 0.97
A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. Leukemia (2013) 0.96
Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner. Exp Hematol (2011) 0.94
Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia. Biol Blood Marrow Transplant (2014) 0.88
Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Genes Cancer (2010) 0.87
A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. Clin Lymphoma Myeloma Leuk (2015) 0.86
Novel targeted drug therapies for the treatment of childhood acute leukemia. Expert Rev Hematol (2009) 0.85
TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo. Blood (2014) 0.85
DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia. Cancer Discov (2016) 0.84
Discovery and characterization of novel mutant FLT3 kinase inhibitors. Mol Cancer Ther (2010) 0.84
Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One (2011) 0.84
Flt3-ITD mutations in a mouse model of radiation-induced acute myeloid leukaemia. Leukemia (2012) 0.83
The Biology and Targeting of FLT3 in Pediatric Leukemia. Front Oncol (2014) 0.83
TrkC promotes survival and growth of leukemia cells through Akt-mTOR-dependent up-regulation of PLK-1 and Twist-1. Mol Cells (2013) 0.83
Will newer tyrosine kinase inhibitors have an impact in AML? Best Pract Res Clin Haematol (2010) 0.83
BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML. Br J Cancer (2011) 0.80
Frequency of acute myeloid leukaemia-associated mouse chromosome 2 deletions in X-ray exposed immature haematopoietic progenitors and stem cells. Mutat Res (2013) 0.80
Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML. Blood Cancer J (2014) 0.80
Pediatric oncology. Curr Opin Chem Biol (2007) 0.80
NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells. Leukemia (2015) 0.79
FLT3 and NPM-1 mutations in a cohort of acute promyelocytic leukemia patients from India. Indian J Hum Genet (2014) 0.79
NADPH oxidase-generated hydrogen peroxide induces DNA damage in mutant FLT3-expressing leukemia cells. J Biol Chem (2015) 0.79
Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition. Exp Hematol (2016) 0.79
High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells. Cancer Lett (2015) 0.78
Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors. Eur J Med Chem (2015) 0.78
FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical Significance. Mediterr J Hematol Infect Dis (2014) 0.78
Calcium and calcineurin-NFAT signaling regulate granulocyte-monocyte progenitor cell cycle via Flt3-L. Stem Cells (2014) 0.77
Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer. PLoS One (2014) 0.77
Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis. Int J Mol Sci (2008) 0.77
Expression of GADS enhances FLT3-induced mitogenic signaling. Oncotarget (2016) 0.77
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol (2016) 0.76
Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients. Adv Hematol (2014) 0.76
Inducible production of recombinant human Flt3 ectodomain variants in mammalian cells and preliminary crystallographic analysis of Flt3 ligand-receptor complexes. Acta Crystallogr Sect F Struct Biol Cryst Commun (2011) 0.76
Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy. Int J Mol Sci (2016) 0.75
Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress. Oncotarget (2016) 0.75
Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes. Cancer Sci (2016) 0.75
The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor. Sci Rep (2016) 0.75
Wnt Signaling: Role in Regulation of Haematopoiesis. Indian J Hematol Blood Transfus (2015) 0.75
Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia. Front Pediatr (2015) 0.75
The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells. Acta Pharmacol Sin (2015) 0.75
Detection of nucleophosmin and FMS-like tyrosine kinase-3 gene mutations in acute myeloid leukemia. Ann Saudi Med (2011) 0.75
Recent advances and novel agents for FLT3 mutated acute myeloid leukemia. Stem Cell Investig (2014) 0.75
Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions. J Clin Med (2014) 0.75
FLT3 inhibitors: clinical potential in acute myeloid leukemia. Onco Targets Ther (2017) 0.75
Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. ACS Med Chem Lett (2016) 0.75
Identification of a germline F692L drug resistance variant in cis with Flt3-internal tandem duplication in knock-in mice. Haematologica (2016) 0.75
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. Oncotarget (2016) 0.75
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv (2017) 0.75
A two-component system that regulates an osmosensing MAP kinase cascade in yeast. Nature (1994) 9.77
Yeast HOG1 MAP kinase cascade is regulated by a multistep phosphorelay mechanism in the SLN1-YPD1-SSK1 "two-component" osmosensor. Cell (1996) 6.87
Enzymatic methods for the determination of small quantities of isomeric chondroitin sulfates. J Biol Chem (1968) 6.28
A novel viral oncogene with structural similarity to phospholipase C. Nature (1988) 5.84
Purification and properties of bacterial chondroitinases and chondrosulfatases. J Biol Chem (1968) 5.66
A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells. Cell (1991) 5.65
Activation of yeast PBS2 MAPKK by MAPKKKs or by binding of an SH3-containing osmosensor. Science (1995) 5.49
Complete primary structure of a heterodimeric T-cell receptor deduced from cDNA sequences. Nature (1984) 5.19
Brefeldin A causes disassembly of the Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum. J Biol Chem (1988) 5.18
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood (2001) 5.17
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia (1996) 5.06
Osmotic activation of the HOG MAPK pathway via Ste11p MAPKKK: scaffold role of Pbs2p MAPKK. Science (1997) 5.02
Developmental regulation of T-cell receptor gene expression. Nature (1985) 4.53
Cadherin-mediated cell-cell adhesion is perturbed by v-src tyrosine phosphorylation in metastatic fibroblasts. J Cell Biol (1992) 4.12
A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell (1998) 3.89
Regulated nucleo/cytoplasmic exchange of HOG1 MAPK requires the importin beta homologs NMD5 and XPO1. EMBO J (1998) 3.87
Array-based genomic resequencing of human leukemia. Oncogene (2010) 3.77
Initiation of the DNA replication of bacteriophage lambda in Escherichia coli K12. J Mol Biol (1977) 3.70
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood (1997) 3.56
Structure, organization, and somatic rearrangement of T cell gamma genes. Cell (1985) 3.49
A third rearranged and expressed gene in a clone of cytotoxic T lymphocytes. Nature (1984) 3.46
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood (1999) 3.46
Signal transduction in neuronal migration: roles of GTPase activating proteins and the small GTPase Cdc42 in the Slit-Robo pathway. Cell (2001) 3.44
Autophagosome requires specific early Sec proteins for its formation and NSF/SNARE for vacuolar fusion. Mol Biol Cell (2001) 3.41
Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res (1996) 3.37
Activation of the c-myc gene by translocation: a model for translational control. Proc Natl Acad Sci U S A (1983) 3.36
Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem (1999) 3.34
Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci U S A (1991) 3.31
A family of receptor-linked protein tyrosine phosphatases in humans and Drosophila. Proc Natl Acad Sci U S A (1989) 3.18
Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens. J Exp Med (1987) 3.14
Complete primary structures of the E beta chain and gene of the mouse major histocompatibility complex. Proc Natl Acad Sci U S A (1983) 3.09
Visualization of neurogenesis in the central nervous system using nestin promoter-GFP transgenic mice. Neuroreport (2000) 3.04
Distinct functional roles of the two intracellular phosphatase like domains of the receptor-linked protein tyrosine phosphatases LCA and LAR. EMBO J (1990) 2.94
Nucleotide sequence of the tobacco mosaic virus (tomato strain) genome and comparison with the common strain genome. J Biochem (1984) 2.93
Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus. Nature (1984) 2.93
ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat Cell Biol (2000) 2.90
Identification of the transcriptional suppressor sof-1 as an alteration in the spo0A protein. J Bacteriol (1985) 2.89
Determination of aminosugar linkages in glycolipids by methylation. Aminosugar linkages of ceramide pentasaccharides of rabbit erythrocytes and of Forssman antigen. Arch Biochem Biophys (1973) 2.87
Organization and expression of the dnaJ and dnaK genes of Escherichia coli K12. Mol Gen Genet (1978) 2.81
Heterothallic Behavior of a Homothallic Strain in Saccharomyces Yeast. Genetics (1958) 2.81
Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res (1996) 2.81
Structural diversity and evolution of human receptor-like protein tyrosine phosphatases. EMBO J (1990) 2.81
Activation of the yeast SSK2 MAP kinase kinase kinase by the SSK1 two-component response regulator. EMBO J (1998) 2.74
A new member of the immunoglobulin superfamily that has a cytoplasmic region homologous to the leukocyte common antigen. J Exp Med (1988) 2.74
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene (2000) 2.73
Amino-terminal presequence of the precursor of peroxisomal 3-ketoacyl-CoA thiolase is a cleavable signal peptide for peroxisomal targeting. Biochem Biophys Res Commun (1991) 2.71
Coding visual images of objects in the inferotemporal cortex of the macaque monkey. J Neurophysiol (1991) 2.70
Regulation of the Saccharomyces cerevisiae HOG1 mitogen-activated protein kinase by the PTP2 and PTP3 protein tyrosine phosphatases. Mol Cell Biol (1997) 2.65
A co-operative numerical analysis of rapidly growing mycobacteria. J Gen Microbiol (1972) 2.63
Limited diversity of the rearranged T-cell gamma gene. Nature (1985) 2.58
Molecular cloning and expression of a member of the aquaporin family with permeability to glycerol and urea in addition to water expressed at the basolateral membrane of kidney collecting duct cells. Proc Natl Acad Sci U S A (1994) 2.54
Transcriptive complex of Newcastle disease virus. I. Both L and P proteins are required to constitute an active complex. Virology (1983) 2.53
Cloning and nucleotide sequence of phoP, the regulatory gene for alkaline phosphatase and phosphodiesterase in Bacillus subtilis. J Bacteriol (1987) 2.52
Structural comparison of the cleavage-activation site of the fusion glycoprotein between virulent and avirulent strains of Newcastle disease virus. Virology (1987) 2.46
High efficiency transformation of maize (Zea mays L.) mediated by Agrobacterium tumefaciens. Nat Biotechnol (1996) 2.43
Regulation of tissue-specific alternative splicing: exon-specific cis-elements govern the splicing of leukocyte common antigen pre-mRNA. EMBO J (1989) 2.41
The 70-kDa peroxisomal membrane protein is a member of the Mdr (P-glycoprotein)-related ATP-binding protein superfamily. J Biol Chem (1990) 2.40
Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost (2006) 2.40
Unusual organization and diversity of T-cell receptor alpha-chain genes. Nature (1985) 2.36
Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc Natl Acad Sci U S A (1998) 2.31
Genetic analysis of two genes, dnaJ and dnaK, necessary for Escherichia coli and bacteriophage lambda DNA replication. Mol Gen Genet (1978) 2.30
Nucleotide sequence of the primary origin of bacteriophage T7 DNA replication: relationship to adjacent genes and regulatory elements. Proc Natl Acad Sci U S A (1980) 2.30
Two-component signal transducers and MAPK cascades. Trends Biochem Sci (1997) 2.29
Tumor necrosis factor provokes superoxide anion generation from neutrophils. Biochem Biophys Res Commun (1986) 2.27
Association of p60src with Triton X-100-resistant cellular structure correlates with morphological transformation. Proc Natl Acad Sci U S A (1987) 2.20
Evaluation of topical pharyngeal anesthesia for upper endoscopy including factors associated with patient tolerance. Gastrointest Endosc (2001) 2.19
Inhibition of GABAA synaptic responses by brain-derived neurotrophic factor (BDNF) in rat hippocampus. J Neurosci (1997) 2.18
Mapping of genes determining nonpermissiveness and host-specific restriction to bacteriophages in Bacillus subtilis Marburg. Mol Gen Genet (1979) 2.17
Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A (1999) 2.17
Protein phosphatase 2Calpha inhibits the human stress-responsive p38 and JNK MAPK pathways. EMBO J (1998) 2.11
Yeast Cdc42 GTPase and Ste20 PAK-like kinase regulate Sho1-dependent activation of the Hog1 MAPK pathway. EMBO J (2000) 2.10
Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology (2001) 2.07
Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis (2000) 2.07
Expression levels of DNA methyltransferase genes do not correlate with p15INK4B gene methylation in myelodysplastic syndromes. Leukemia (2003) 2.06
Analysis of local and wide-field movements in the superior temporal visual areas of the macaque monkey. J Neurosci (1986) 2.03
Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet (2000) 2.02
Nucleotide sequence of the Bacillus subtilis phoR gene. J Bacteriol (1988) 2.02
Mutations in a protein tyrosine phosphatase gene (PTP2) and a protein serine/threonine phosphatase gene (PTC1) cause a synthetic growth defect in Saccharomyces cerevisiae. Mol Cell Biol (1993) 2.01
Prenatal DNA diagnosis of a single-gene disorder from maternal plasma. Lancet (2000) 2.01
Molecular cloning and characterization of a novel human gene (HERNA) which encodes a putative RNA-helicase. Biochim Biophys Acta (2000) 1.97
Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. Biochem Biophys Res Commun (1997) 1.97
Analysis of motion of the visual field by direction, expansion/contraction, and rotation cells clustered in the dorsal part of the medial superior temporal area of the macaque monkey. J Neurophysiol (1989) 1.95
Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci U S A (1988) 1.93
Characterization of a novel acidic protein of 38 kDa, A0, in yeast ribosomes which immunologically cross-reacts with the 13 kDa acidic ribosomal proteins, A1/A2. J Biochem (1987) 1.93
An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol (2000) 1.93
Early sporulation gene spo0F: nucleotide sequence and analysis of gene product. Proc Natl Acad Sci U S A (1983) 1.91
Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc Natl Acad Sci U S A (1998) 1.90
Demonstration of mother-to-infant transmission of hepatitis B virus by means of polymerase chain reaction. Lancet (1989) 1.90
Cloning of the ALL-1 fusion partner, the AF-6 gene, involved in acute myeloid leukemias with the t(6;11) chromosome translocation. Cancer Res (1993) 1.89
Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother (1992) 1.89
The effect of spo0 mutations on the expression of spo0A- and spo0F-lacZ fusions. Mol Gen Genet (1986) 1.89